Eli Lilly issues press release on retatrutide Phase 3 obesity trial results - LLY News | RalliesEli Lilly issues press release on retatrutide Phase 3 obesity trial results
L
LLY• Phase 3 trial results for retatrutide
- Eli Lilly posted a press release disclosing positive topline Phase 3 results for obesity drug candidate retatrutide in TRIUMPH-2, TRIUMPH-3.
- TRIUMPH-2 showed up to 20.8% average weight loss at 80 weeks in adults with obesity or overweight, type 2 diabetes.
- TRIUMPH-3 showed up to 22.6% average weight loss at 80 weeks in severe obesity with established cardiovascular disease.
- FDA Biologics License Application filing targeted for Q1 2027.
BLIN
•
